- Home
- AMTB vs CMPX Comparison
AMTB vs CMPX Comparison
Compare AMTB & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMTB
- CMPX
- Stock Information
- Founded
- AMTB 1979
- CMPX 2014
- Country
- AMTB United States
- CMPX United States
- Employees
- AMTB N/A
- CMPX N/A
- Industry
- AMTB Major Banks
- CMPX Biotechnology: Pharmaceutical Preparations
- Sector
- AMTB Finance
- CMPX Health Care
- Exchange
- AMTB Nasdaq
- CMPX Nasdaq
- Market Cap
- AMTB 726.3M
- CMPX 752.4M
- IPO Year
- AMTB N/A
- CMPX N/A
- Fundamental
- Price
- AMTB $19.04
- CMPX $5.35
- Analyst Decision
- AMTB Buy
- CMPX Strong Buy
- Analyst Count
- AMTB 4
- CMPX 7
- Target Price
- AMTB $21.75
- CMPX $14.43
- AVG Volume (30 Days)
- AMTB 348.2K
- CMPX 2.1M
- Earning Date
- AMTB 10-28-2025
- CMPX 11-05-2025
- Dividend Yield
- AMTB 1.90%
- CMPX N/A
- EPS Growth
- AMTB N/A
- CMPX N/A
- EPS
- AMTB 1.59
- CMPX N/A
- Revenue
- AMTB $388,504,000.00
- CMPX N/A
- Revenue This Year
- AMTB $61.98
- CMPX N/A
- Revenue Next Year
- AMTB $4.00
- CMPX N/A
- P/E Ratio
- AMTB $11.94
- CMPX N/A
- Revenue Growth
- AMTB 51.98
- CMPX N/A
- 52 Week Low
- AMTB $15.62
- CMPX $1.33
- 52 Week High
- AMTB $26.24
- CMPX $5.39
- Technical
- Relative Strength Index (RSI)
- AMTB 63.49
- CMPX 76.02
- Support Level
- AMTB $16.81
- CMPX $4.73
- Resistance Level
- AMTB $17.74
- CMPX $5.16
- Average True Range (ATR)
- AMTB 0.49
- CMPX 0.32
- MACD
- AMTB 0.26
- CMPX 0.05
- Stochastic Oscillator
- AMTB 98.94
- CMPX 97.48
About AMTB Amerant Bancorp Inc.
Amerant Bancorp Inc is a bank holding company. Through its bank, it provides individuals and businesses deposit, credit, investment, wealth management, and fiduciary services, both in the United States and to select international customers. The bank also provides banking services through traditional channels, such as banking centers and ATMs, as well as via secure websites, mobile devices and telephones.
About CMPX Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.